Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit, titled Makaveev v. RxSight, Inc., et al., is pending in the U.S. District Court for the Central District of California, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors, leading to a significant stock price decline [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, resulting in a 38% drop in stock price from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, led to another 38% decline in stock price, dropping from $12.79 to $7.95 per share [6].

Core Viewpoint - A class action securities lawsuit has been filed against Novo Nordisk A/S, alleging securities fraud that negatively impacted investors between May 7, 2025, and July 28, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Novo Nordisk made overly positive statements while concealing material adverse facts about its growth potential, particularly regarding the compounded GLP-1 market and the likelihood of patients switching to its branded alternatives [2]. - On July 29, 2025, Novo announced a reduction in its sales and profit outlook for the second half of 2025, attributing this to lower growth expectations for its products Wegovy and Ozempic, due to competition and the persistent use of compounded GLP-1s [2]. - Following the announcement, Novo's stock price plummeted from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, marking a decline of approximately 21.83% in one day [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until September 30, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. due to alleged securities fraud affecting investors between November 7, 2024, and July 8, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the defendants overstated the demand for RxSight's products [2]. - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 as a result of these issues [2]. - Positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record, having secured hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

BENSALEM, Pa., Aug. 5, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Fiserv, Inc. ("Fiserv" or the "Company") (NYSE: FI). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN FISERV, INC. (FI), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE SEPTEMBER 22, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smi ...

Core Viewpoint - Novo Nordisk (NVO.US) faces a decline of over 2% in stock price to $47.64 due to a downward revision of its annual revenue and operating profit growth expectations, linked to challenges in the GLP-1 market [1] Group 1: Legal Issues - A group of shareholders has filed a proposed class action lawsuit against Novo Nordisk in federal court in New Jersey, seeking compensation for alleged securities fraud from May 7 to July 28, 2025 [1] - The plaintiffs accuse Novo Nordisk of making overly optimistic statements and disseminating false and misleading information, exaggerating its growth potential while concealing significant adverse facts [1] - The lawsuit claims that the downward revision of performance guidance led to a sharp decline in stock price, resulting in shareholder losses [1]

Core Viewpoint - Novo Nordisk (NVO.US) faces a decline of over 2% in stock price to $47.64 due to a downward revision of its annual revenue and operating profit growth expectations, citing challenges in the GLP-1 market as the reason for the adjustment [1] Group 1: Legal Issues - A group of shareholders has filed a proposed class action lawsuit against Novo Nordisk in a federal court in New Jersey, seeking compensation for losses allegedly caused by securities fraud between May 7, 2025, and July 28, 2025 [1] - The plaintiffs accuse Novo Nordisk of making overly optimistic statements and disseminating false and misleading information, exaggerating its growth potential while concealing significant adverse facts [1] - The lawsuit claims that the downward revision of performance guidance led to a sharp decline in stock price, resulting in shareholder losses [1]

Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation and certain officers for alleged violations of federal securities laws during the Class Period from January 29, 2024, to March 11, 2025, seeking damages for affected investors [1][2]. Company Overview - iRobot designs, builds, and sells robots and home innovation products globally, primarily known for its Roomba robot vacuum cleaner [4]. - The company has faced declining business performance over the past decade, with market share dropping from 64% in 2016 to 46% in 2020 due to competition from lower-priced alternatives [5]. Recent Developments - In August 2022, iRobot entered a merger agreement with Amazon for $61 per share, valued at approximately $1.7 billion, but the deal was terminated in January 2024 due to regulatory concerns [6]. - Following the termination, iRobot announced significant layoffs, cutting approximately 350 employees, or 31% of its workforce, and a restructuring plan aimed at stabilizing the company [7]. Financial Performance - iRobot reported a loss of $2.06 per share on revenue of $172 million for Q4 2024, marking a 44% year-over-year decline [9]. - The company expressed substantial doubt about its ability to continue as a going concern for at least 12 months following the issuance of its 2024 financial statements [9]. Market Reaction - Following the negative financial results and outlook, iRobot's stock price fell by $3.255 per share, or 51.58%, over two trading sessions [10]. - Despite a short squeeze in May 2025 due to delayed U.S. tariffs on EU imports, analysts noted that iRobot's underlying financial fundamentals remained concerning, with deteriorating cash reserves and operational stress [11].

NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Petco Health and Wellness Company, Inc. ("Petco" or the "Company") (NASDAQ: WOOF) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Petco investors who were adversely affected by alleged securities fraud between January 14, 2021 and June 5, 2025. Follow the link below to get more information and be contacted by a member of our team: CASE DETAILS: (i) Petco's pandemic-rela ...

Core Viewpoint - Novo Nordisk (NVO.US) is facing a shareholder lawsuit due to a downward revision of its full-year revenue and operating profit growth expectations, citing challenges in the GLP-1 market as the reason for the adjustment [1] Group 1: Stock Performance - The company's American Depositary Receipts (ADR) experienced a significant drop of over 20% last Tuesday, marking the largest intraday decline since 1987 [1] Group 2: Legal Actions - A group of shareholders filed a proposed class-action lawsuit in federal court in New Jersey on July 28, seeking damages for alleged securities fraud occurring between May 7 and July 28, 2025 [1] - The plaintiffs accuse Novo Nordisk of making overly optimistic statements and disseminating false and misleading information, exaggerating its growth potential while concealing significant adverse facts [1] - The lawsuit claims that the stock price collapse resulting from the lowered performance guidance led to substantial losses for shareholders [1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Lockheed Martin Corporation, alleging violations of the Securities Exchange Act of 1934 due to misrepresentations regarding the company's internal controls and risk-adjusted profit booking rate [3][4]. Group 1: Lawsuit Details - The lawsuit was initiated on behalf of investors who purchased Lockheed Martin securities between January 23, 2024, and July 21, 2025 [3]. - Defendants in the lawsuit include the company and certain senior officers, accused of making false statements about the company's internal controls [4]. Group 2: Legal Process and Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by September 26, 2025, although participation as a lead plaintiff is not required to share in any potential recovery [5]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation [6].